Mirum Pharmaceuticals, Inc.

MIRM

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001759425

B

second fifth of 369 graded peers in healthcare

rank 87 of 369; percentile 23.4; sampling error 2.5 points; lower is stronger

A B C D E

B, the elk



Scoreboard

Profitability	B/C percentile 40.0
Solvency	C percentile 51.5
Growth and financing	B percentile 27.5
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $842.8M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Feb 25, 2026 252 days before the rescan; latest periodic filing 10-Q received Nov 3, 2026
Last close	$87.01 2026-11-03; market equity $5.7B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 25, 2026

We are a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We have three approved medicines: LIVMARLI® (maralixibat) ("Livmarli"), CHOLBAM® (cholic acid) capsules ("Cholbam"), and CTEXLI® (chenodiol) tablets ("Ctexli").

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 40.0						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(10.5%)	(6.6%)		40.0	803	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 51.5					
Twelve-month failure probability	0.13%	0.08%	58.9	247	2026-09-30
Altman Z double-prime	0.54	(0.35)	35.1	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	2.67x	2.92x	60.5	828	2025-12-31
Growth and financing, sleeve percentile 27.5					
Revenue growth, three-year compound	89.1%	10.1%	6.3	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	33.7%	2.2%	13.9	697	2025-12-31
Net share issuance, one year	23.1%	2.5%	62.1	632	2026-02-20

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
82	Axsome Therapeutics, Inc. (AXSM)	22.0	A/B	
83	Rigel Pharmaceuticals Inc. (RIGL)	22.3	A/B	
84	Halozyme Therapeutics, Inc. (HALO)	22.6	B	
85	Lineage Cell Therapeutics, Inc. (LCTX)	22.8	B	
86	Puma Biotechnology, Inc. (PBYI)	23.1	B	fortress balance sheet
87	Mirum Pharmaceuticals, Inc. (MIRM)	23.4	B	
88	Warby Parker Inc. (WRBY)	23.6	B	
89	Sarepta Therapeutics, Inc. (SRPT)	23.9	B	
90	Guardant Health, Inc. (GH)	24.2	B	
91	Cronos Group Inc. (CRON)	24.5	B	
92	4D Molecular Therapeutics, Inc. (FDMT)	24.7	B	dilution, short runway

What the price implies

at the 2026-11-03 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	17.7%	(2.2%)	61
Distance from 52-week high	(32.3%)	(29.8%)	45
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	1.0%	(0.9%)	60
Book value to price	(0.01)	0.28	10

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	0.09	0.30	24
Composite equity issuance, five years	76.4%	20.5%	72
Relative strength against the sector, log excess return	(0.01)	(0.19)	61

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$243.2M
Operating cash flow, four quarters	-$271.3M
Months of runway	10.8
Days since last periodic filing	1 (10-Q received Nov 3, 2026)
Median daily dollar volume, 63 sessions	$56.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$23.4M	2025-12-31	2026-02-25	10-K	26-000013
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$55.8M	2025-12-31	2026-02-25	10-K	26-000013
3	assets	us-gaap:Assets	$842.8M	2025-12-31	2026-02-25	10-K	26-000013
4	assets	us-gaap:Assets	$670.8M	2024-12-31	2026-02-25	10-K	26-000013
5	current assets	us-gaap:AssetsCurrent	$549.7M	2025-12-31	2026-02-25	10-K	26-000013
6	current liabilities	us-gaap:LiabilitiesCurrent	$205.8M	2025-12-31	2026-02-25	10-K	26-000013
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$667.5M	2025-12-31	2026-02-25	10-K	26-000013
8	operating income	us-gaap:OperatingIncomeLoss	-$22.1M	2025-12-31	2026-02-25	10-K	26-000013
9	book equity	us-gaap:StockholdersEquity	$314.7M	2025-12-31	2026-02-25	10-K	26-000013
10	liabilities	us-gaap:Liabilities	$528.1M	2025-12-31	2026-02-25	10-K	26-000013
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$521.3M	2025-12-31	2026-02-25	10-K	26-000013
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$336.9M	2024-12-31	2026-02-25	10-K	26-000013
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$186.4M	2023-12-31	2026-02-25	10-K	26-000013
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$77.1M	2022-12-31	2025-02-26	10-K	25-000014
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$954,000	2025-12-31	2026-02-25	10-K	26-000013
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$10.3M	2024-12-31	2026-02-25	10-K	26-000013
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$993,000	2024-12-31	2026-02-25	10-K	26-000013
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$70.9M	2023-12-31	2026-02-25	10-K	26-000013
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$109,000	2023-12-31	2026-02-25	10-K	26-000013
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$120.1M	2022-12-31	2025-02-26	10-K	25-000014
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$278,000	2022-12-31	2025-02-26	10-K	25-000014
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$24.2M	2025-12-31	2026-02-25	10-K	26-000013
23	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$21.4M	2025-12-31	2026-02-25	10-K	26-000013
24	income tax	us-gaap:IncomeTaxExpenseBenefit	$1.9M	2025-12-31	2026-02-25	10-K	26-000013
25	current assets	us-gaap:AssetsCurrent	$392.8M	2024-12-31	2026-02-25	10-K	26-000013
26	current liabilities	us-gaap:LiabilitiesCurrent	$126.6M	2024-12-31	2026-02-25	10-K	26-000013
27	assets	us-gaap:Assets	$646.6M	2023-12-31	2025-02-26	10-K	25-000014

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	assets	us-gaap:Assets	$352.9M	2022-12-31	2024-03-15	10-K	24-032289
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	60,341,617	2026-02-20	2026-02-25	10-K	26-000013
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,014,190	2025-02-21	2025-02-26	10-K	25-000014